AU2004207647B2 - Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide - Google Patents

Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide Download PDF

Info

Publication number
AU2004207647B2
AU2004207647B2 AU2004207647A AU2004207647A AU2004207647B2 AU 2004207647 B2 AU2004207647 B2 AU 2004207647B2 AU 2004207647 A AU2004207647 A AU 2004207647A AU 2004207647 A AU2004207647 A AU 2004207647A AU 2004207647 B2 AU2004207647 B2 AU 2004207647B2
Authority
AU
Australia
Prior art keywords
polysaccharide
formula
conjugate
aminated
reductive amination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004207647A
Other languages
English (en)
Other versions
AU2004207647A1 (en
Inventor
Emilie Danve
Noelle Mistretta
Monique Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AU2004207647A1 publication Critical patent/AU2004207647A1/en
Application granted granted Critical
Publication of AU2004207647B2 publication Critical patent/AU2004207647B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004207647A 2003-01-17 2004-01-16 Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide Expired AU2004207647B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR03/00488 2003-01-17
FR0300488A FR2850106B1 (fr) 2003-01-17 2003-01-17 Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PCT/FR2004/000089 WO2004067574A1 (fr) 2003-01-17 2004-01-16 Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5

Publications (2)

Publication Number Publication Date
AU2004207647A1 AU2004207647A1 (en) 2004-08-12
AU2004207647B2 true AU2004207647B2 (en) 2010-07-01

Family

ID=32605815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004207647A Expired AU2004207647B2 (en) 2003-01-17 2004-01-16 Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide

Country Status (13)

Country Link
US (1) US7812006B2 (enExample)
EP (1) EP1590373B1 (enExample)
KR (1) KR101044437B1 (enExample)
AT (1) ATE520718T1 (enExample)
AU (1) AU2004207647B2 (enExample)
BR (1) BRPI0406819B1 (enExample)
CA (1) CA2512847C (enExample)
DK (1) DK1590373T3 (enExample)
FR (1) FR2850106B1 (enExample)
IL (1) IL169689A0 (enExample)
MX (1) MXPA05007533A (enExample)
NZ (1) NZ541254A (enExample)
WO (1) WO2004067574A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
EP2425853A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US9522382B2 (en) * 2011-09-06 2016-12-20 Biologistics Llc Affinity/lectin chromatography methods
EP2755683B1 (en) * 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3303357B1 (en) * 2015-06-08 2021-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against streptococcus pneumoniae serotype 5
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018156467A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20230405137A1 (en) * 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120607643B (zh) * 2025-07-24 2026-05-12 江苏中慧元通生物科技股份有限公司 一种肺炎球菌单价多糖的纯化工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596861B1 (en) * 1999-03-12 2003-07-22 Aventis Pasteur S.A. Method for the reductive amination of polysaccharides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596861B1 (en) * 1999-03-12 2003-07-22 Aventis Pasteur S.A. Method for the reductive amination of polysaccharides

Also Published As

Publication number Publication date
BRPI0406819A (pt) 2005-12-27
KR101044437B1 (ko) 2011-06-27
WO2004067574A1 (fr) 2004-08-12
NZ541254A (en) 2008-07-31
CA2512847C (en) 2012-08-21
EP1590373B1 (fr) 2011-08-17
KR20050093838A (ko) 2005-09-23
US7812006B2 (en) 2010-10-12
IL169689A0 (en) 2007-07-04
FR2850106B1 (fr) 2005-02-25
CA2512847A1 (en) 2004-08-12
EP1590373A1 (fr) 2005-11-02
AU2004207647A1 (en) 2004-08-12
BRPI0406819B1 (pt) 2017-01-03
FR2850106A1 (fr) 2004-07-23
BRPI0406819B8 (enExample) 2021-05-25
DK1590373T3 (da) 2011-12-05
ATE520718T1 (de) 2011-09-15
US20040170638A1 (en) 2004-09-02
MXPA05007533A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
CA2512847C (en) Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide
EP1109576B1 (en) Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
JP4290766B2 (ja) 多糖―ペプチド複合体
JP3676803B2 (ja) 病原体から得られる抗原多糖から誘導されたオリゴ糖
US20080008709A1 (en) Conjugation of biomolecules using Diels-Alder cycloaddition
US11191822B2 (en) Pneumococcal polysaccharide-protein conjugate composition
JP2020523323A (ja) 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
AU2017234319B2 (en) Novel polysaccharide-protein conjugates and process to obtain thereof
AU3432500A (en) Method for the reductive amination of polysaccharides
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
MXPA03010283A (es) Conjugados inmunogenicos de acido hialuronico de peso molecular bajo con toxinas de polipeptido.
KR101266552B1 (ko) 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
US5952454A (en) Linking compounds useful for coupling carbohydrates to amine-containing carriers
US11097000B2 (en) Klebsiella pneumoniae capsule polysaccharide vaccines
WO2025021704A1 (en) Vaccine
RU2476444C1 (ru) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА НОНА-β-(1→3)-ГЛЮКОЗИДА С БЫЧЬИМ СЫВОРОТОЧНЫМ АЛЬБУМИНОМ СКВАРАТНЫМ МЕТОДОМ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired